The Week That Was: COVID-19 Drug/Vaccine Development Landscape

(RTTNews) - The deadly pathogen SARS-COV-2, which causes COVID-19, continues to spread unabated in most parts of the world while in some regions it has been brought under control. At last count, the total number of confirmed cases of infection across the globe is 5.31 million and the death toll is 342,147. The U.S. tops the list with 1.62 million confirmed cases and 97,087 fatalities, according to Johns Hopkins University. As the companies race against time to develop antibiotics or vaccines against the novel coronavirus, here's what happened in the COVID-19 drug/vaccine development space in the week that went by. 1. Moderna's COVID-19 Vaccine Candidate On Track For Phase II Study Moderna Inc.'s (MRNA) vaccine candidate against the novel coronavirus, mRNA-1273, has yielded positive results in a phase I study that was led by the National Institute of Allergy and Infectious Diseases. In the phase I study, all eight participants evaluated to date across the 25 µg and 100 µg dose cohorts of mRNA-1273 developed detectable antibodies in the blood against the novel coronavirus at or above levels seen in convalescent sera. In addition, the vaccine candidate elicited neutralizing antibody titer levels in all the participants across the 25 µg The post The Week That Was: COVID-19 Drug/Vaccine Development Landscape appeared first on Asset Management - How To Asset Manage. Seoul, Korea
http://dlvr.it/RXFj3V